Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1089 blog entries.

September 2022

Conversation with Esther Abels, President of The Digital Pathology Association, and Chief Clinical and Regulatory Officer at Visiopharm

2022-09-26T15:05:13+00:00

The DPA has a lot of stakeholders. We include these stakeholders in our discussions so that we can stay on top of the new developments... ...our approach is to look at all these techniques and ask how we can leverage them and how can we use them to optimize digital pathology.

Conversation with Esther Abels, President of The Digital Pathology Association, and Chief Clinical and Regulatory Officer at Visiopharm2022-09-26T15:05:13+00:00

Interview with Deep Bio’s CEO, Sun Woo Kim

2022-09-26T10:53:21+00:00

Deep Bio was founded with the transformative mission: To advance patient outcomes by driving innovation in technology, while empowering clinicians by providing the tools to make critical decisions. They envision a world where clinicians are empowered with technology designed to unlock personalized insights and enhance healthcare delivery, so they can focus more on what they do best: caring for their patients.

Interview with Deep Bio’s CEO, Sun Woo Kim2022-09-26T10:53:21+00:00

Paige and OptraSCAN Partner to Streamline Digital Pathology Adoption

2022-09-23T10:33:47+00:00

Together, the companies will integrate Paige’s clinical AI applications and interoperable enterprise imaging platform with OptraSCAN’s digital pathology scanner to offer advanced end-to-end digital pathology workflow solutions. This provides a streamlined path for pathologists to adopt Paige’s leading suite of digital pathology applications, including the FDA-cleared FullFocus® whole-slide image viewer and AI applications including Paige Prostate Suite and Paige Breast Suite alongside OptraSCAN’s affordable digital pathology scanners. OptraSCAN devices have 15 to 480 slide loading capabilities that digitize the glass slides at 40x in less than one minute per slide with patented composite imaging offering.“We are excited to work with OptraSCAN to make it easier for labs and healthcare networks around the world to adopt digital pathology workflows,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “This collaboration is an important step in our mission to unlock the full potential of AI in routine clinical use and provide healthcare professionals with precise insights to help patients get the most effective care.”Abhi Gholap, Founder and CEO of OptraSCAN said, “OptraSCAN’s mission to enable pathology slide digitization at fractional costs is eventually resulting into higher market demand for digital pathology applications. This partnership with Paige will facilitate adoption of digital infrastructure for global clinical and molecular pathology community in an efficient way.”About PaigePaige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.For additional information, please visit: https://www.Paige.ai, Twitter and LinkedIn.About OptraSCAN, Inc.OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput or global location.OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model.Please visit www.optrascan.com

Paige and OptraSCAN Partner to Streamline Digital Pathology Adoption2022-09-23T10:33:47+00:00

Remote Toxicologic Pathology. How Deciphex is Accelerating the Non-clinical Drug Development Phase W/ Donal O’shea

2025-05-06T13:33:58+00:00

Donal O’Shea, the CEO, and founder of Deciphex has been active in the area of digital pathology essentially since its beginning. He worked in academia and founded several successful digital pathology start-ups before creating his own.

Remote Toxicologic Pathology. How Deciphex is Accelerating the Non-clinical Drug Development Phase W/ Donal O’shea2025-05-06T13:33:58+00:00

Linköping University Hospital Embraces EIZO Monitors to Digitize Its Workflow

2022-09-21T07:45:22+00:00

To implement a digital pathology workflow at Linköping University Hospital in Sweden, consultant pathologist Anna Bodén MD decided to proceed with the purchase of a fleet of EIZO RadiForce RX850 monitors. All glass slides with thin tissue sections are now scanned and digital diagnostics are conducted on 20 workstations, all equipped with RadiForce RX850 monitors. Digitization of [...]

Linköping University Hospital Embraces EIZO Monitors to Digitize Its Workflow2022-09-21T07:45:22+00:00

An Insight into Jill Stefanelli’s Impact on the Digital Pathology Space | Paige Turners

2022-09-20T08:26:35+00:00

Paige Turners highlights technology innovators, medical trailblazers, and business visionaries making an impact in the digital pathology, artificial intelligence, and cancer care space.   In this edition, we spoke with Jill Stefanelli, President and Chief Business Officer at Paige.  President and Chief Business Officer at Paige, Jill Stefanelli, first got her start in the oncology space about 15 [...]

An Insight into Jill Stefanelli’s Impact on the Digital Pathology Space | Paige Turners2022-09-20T08:26:35+00:00

Drs. Eloy and Bryson Validate Paige Prostate Diagnostic AI in Clinical Setting

2022-09-16T07:59:05+00:00

At the 2022 European Congress of Pathology (ECP) in Basel, Switzerland, Paige’s Medical Director Dr. Juan Retamero moderated a symposium featuring Dr. Catarina Eloy, Head of Pathology Lab at IPATIMUP and Dr. Gareth Bryson, Consultant Pathologist and Clinical Director for Laboratory Medicine at NHS Greater Glasgow and Clyde, where they discussed the impacts of digital pathology and AI in [...]

Drs. Eloy and Bryson Validate Paige Prostate Diagnostic AI in Clinical Setting2022-09-16T07:59:05+00:00

Unilabs Selects Proscia’s AI For Skin Pathology

2022-09-15T07:10:40+00:00

Unilabs, a leading diagnostic services provider, and Proscia®, a leading provider of digital and computational pathology solutions, today announced that the diagnostic group has chosen Proscia’s DermAI®* to advance its aspiration of becoming the most digitally-driven diagnostic group – enabling better decisions for a healthier tomorrow. The artificial intelligence (AI)-enabled technology will first be deployed in Sweden and then rolled out across other countries where Unilabs serves patients.

Unilabs Selects Proscia’s AI For Skin Pathology2022-09-15T07:10:40+00:00

What is validation and how to validate an AI image analysis solution w/ Tom Westerling-Bui from Aiforia

2025-05-06T13:35:04+00:00

The tools to develop AI models for biomedical image analysis have recently become accessible also for non-computer scientists. With the accessibility to AI tools, the question arises whether the things we build are good enough?

What is validation and how to validate an AI image analysis solution w/ Tom Westerling-Bui from Aiforia2025-05-06T13:35:04+00:00

Researchers Forewarn the Misuse and Overuse of Machine Learning (ML) in Healthcare Research

2022-09-13T15:04:01+00:00

An international team of researchers, writing in the journal Nature Medicine, advises that strong care needs to be taken not to misuse or overuse machine learning (ML) in healthcare research. "I absolutely believe in the power of ML but it has to be a relevant addition," said neurosurgeon-in-training and statistics editor Dr Victor Volovici, first author of the comment, from Erasmus MC University Medical Center, The Netherlands. "Sometimes ML algorithms do not perform better than traditional statistical methods, leading to the publication of papers that lack clinical or scientific value." Real world examples have shown that the misuse of algorithms in healthcare could perpetuate human prejudices or inadvertently cause harm when the machines are trained on biased datasets. "Many believe ML will revolutionise healthcare because machines make choices more objectively than humans. But without proper oversight, ML models may do more harm than good," said Associate Professor Nan Liu, senior author of the comment, from the Centre for Quantitative Medicine and Health Services & Systems Research Programme at Duke-NUS Medical School, Singapore. "If, through ML, we uncover patterns that we otherwise would not see -- like in radiology and pathology images -- we should be able to explain how the algorithms got there, to allow for checks and balances." Together with a group of scientists from the UK and Singapore, the researchers highlight that although guidelines have been formulated to regulate the use of ML in clinical research, these guidelines are only applicable once a decision to use ML has been made and do not ask whether or when its use is appropriate in the first place. For example, companies have successfully trained ML algorithms to recognise faces and road objects using billions of images and videos. But when it comes to their use in healthcare settings, they are often trained on data in the tens, hundreds or thousands. "This underscores the relative poverty of big data in healthcare and the importance of working towards achieving sample sizes that have been attained in other industries, as well as the importance of a concerted, international big data sharing effort for health data," the researchers write. Another issue is that most ML and deep learning algorithms (that do not receive explicit instructions regarding the outcome) are often still regarded as a 'black box'. For example, at the start of the COVID-19 pandemic, scientists published an algorithm that could predict coronavirus infections from lung photos. Afterwards, it turned out that the algorithm had drawn conclusions based on the imprint of the letter 'R' (for 'Right Lung') in the photos, which was always found in a slightly different spot on the scans. "We have to get rid of the idea that ML can discover patterns in data that we cannot understand," said Dr Volovici about the incident. "ML can very well discover patterns that we cannot see directly, but then you have to be able to explain how you came to that conclusion. In order to do that, the algorithm has to be able to show what steps it took, and that requires innovation." The researchers advise that ML algorithms should be evaluated against traditional statistical approaches (when applicable) before they are used in clinical research. And when deemed appropriate, they should complement clinician decision-making, rather than replace it. "ML researchers should recognise the limits of their algorithms and models in order to prevent their overuse and misuse, which could otherwise sow distrust and cause patient harm," the researchers write. The team is working on organising an international effort to provide guidance on the use of ML and traditional statistics, and also to set up a large database of anonymised clinical data that can harness the power of ML algorithms. Story Source: Materials provided by Duke-NUS Medical School. Note: Content may be edited for style and length.

Researchers Forewarn the Misuse and Overuse of Machine Learning (ML) in Healthcare Research2022-09-13T15:04:01+00:00
Go to Top